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Age-related macular degeneration (AMD) is one of the most common eye diseases of elderly individuals. It has been suggested that lutein
and zeaxanthin may reduce the risk for AMD. Information concerning the absorption of non-esterified or esterified zeaxanthin is rather
scarce. Furthermore, the formation pathway of meso (3R,30S)-zeaxanthin, which does not occur in plants but is found in the macula,
has not yet been identified. Thus, the present study was designed to assess the concentration of 3R,3R0-zeaxanthin reached in plasma
after the consumption of a single dose of native 3R,30R-zeaxanthin palmitate from wolfberry (Lycium barbarum) or non-esterified
3R,30R-zeaxanthin in equal amounts. In a randomised, single-blind cross-over study, twelve volunteers were administered non-esterified
or esterified 3R,30R-zeaxanthin (5 mg) suspended in yoghurt together with a balanced breakfast. Between the two intervention days, a
3-week depletion period was inserted. After fasting overnight, blood was collected before the dose (0 h), and at 3, 6, 9, 12, and 24 h
after the dose. The concentration of non-esterified 3R,30R-zeaxanthin was determined by chiral HPLC. For the first time, chiral liquid
chromatography–atmospheric pressure chemical ionisation-MS was used to confirm the appearance of 3R,30R-zeaxanthin in pooled
plasma samples. Independent of the consumed diet, plasma 3R,30R-zeaxanthin concentrations increased significantly (P¼0·05) and
peaked after 9–24 h. Although the concentration curves were not distinguishable, the respective areas under the curve were distinguishable
according to a two-sided F and t test (P¼0·05). Thus, the study indicates an enhanced bioavailability of 3R,30R-zeaxanthin dipalmitate
compared with the non-esterified form. The formation of meso-zeaxanthin was not observed during the time period studied.
3R,30R-zeaxanthin: Zeaxanthin esters: Plasma carotenoid response: Chiral analysis: Liquid chromatography–atmospheric
pressure chemical ionisation-mass spectrometry
Zeaxanthin (b,b-carotene-3,30-diol) is a xanthophyll
widely distributed in fruits and vegetables. Data concern-
ing the zeaxanthin concentration of plants have been speci-
fied by several authors (Sommerburg et al. 1998; Murkovic
et al. 2000; Breithaupt & Bamedi, 2001). Recently, a study
investigating zeaxanthin esters in plants with potential use
for zeaxanthin oleoresin production was published (Weller
& Breithaupt, 2003). During the last decade, lutein and
zeaxanthin attracted attention as both xanthophylls were
found to be specifically located in the human macula (for
example, Bernstein et al. 2001; Landrum & Bone, 2001).
Relying on epidemiological data, it is anticipated that a
high serum concentration of lutein and zeaxanthin could
protect from age-related macular degeneration and age-
related cataract formation (for example, Mares-Perlman
et al. 2002). The enrichment of the daily human diet
with zeaxanthin-containing plants has been known for a
long time; for example, wolfberries (Lycium barbarum;
Gou Qi Zi), small red berries commonly used in home
cooking in China, were traditionally used in Chinese
herbal medicine for the improvement of visual acuity.
The main phytochemical found in this plant source,
which is regarded as the active component, is zeaxanthin
dipalmitate, a diester formed from zeaxanthin and palmitic
acid (Lam & But, 1999; Zhou et al. 1999; Barua, 2001).
Leung et al. (2001) used rhesus monkeys to study the
serum and tissue levels of zeaxanthin and lutein after feed-
ing Gou Qi Zi extracts.
Due to the two chiral centres at the carbon atoms C3 and
C3
0, the positions of the secondary hydroxyl groups, zea-
xanthin theoretically exists in three stereoisomeric forms:
3R,30R-, 3S,30S- and 3R,30S-zeaxanthin; the latter is also
referred to as meso-zeaxanthin. In plants, usually 3R,30R-
zeaxanthin occurs as the only form, whereas in shrimp,
fish, and reptiles all enantiomers can be present in parallel
(Maoka et al. 1986). Xanthophylls extracted from human
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retina, analysed after derivatisation on reversed-phase
columns, showed that only two forms were present:
3R,30R- and meso-zeaxanthin. Besides zeaxanthin enantio-
mers, lutein was detected in its native 3R,30R,60R form
(Bone et al. 1993). The authors postulated that meso-zea-
xanthin, which is not of dietary origin, is generated from
3R,30R,60R-lutein present in the retina of the eye. However,
the process is not yet sufficiently understood. Khachik et al.
(2002), who found no meso-zeaxanthin in human plasma
and liver, postulated double-bond isomerisation as the
metabolic pathway for the generation of the meso form.
Landrum & Bone (2001) suggested 30-oxolutein as an
intermediate in the conversion mechanism within the
retina. However, the potential formation of meso-zea-
xanthin after the ingestion of 3R,30R-zexanthin-enriched
diets has not been studied so far.
Dietary xanthophyll esters are hydrolysed during the
digestion process before absorption occurs (Wingerath
et al. 1995). Data comparing the resorption characteristics
of esterified and non-esterified zeaxanthin are however not
yet available. Comparable work has been done on lutein
and its esters (Bowen et al. 2002) and on b-cryptoxanthin
(Breithaupt et al. 2003). Pe´rez-Ga´lvez et al. (2003)
recently reported that capsanthin from paprika oleoresin
ingested as a single dose (1 g) was not detected in
plasma at all. However, the authors did not use a control
group to study the bioavailability of the corresponding
non-esterified xanthophylls but concluded that lipases did
not cleave esters of oxocarotenoids such as capsanthin.
Consequently, we designed a cross-over study using
native 3R,30R-zeaxanthin dipalmitate from wolfberries or
non-esterified 3R,30R-zeaxanthin, obtained after alkaline
hydrolysis. The supplements were applied as one single
dose together with a balanced breakfast. For the identifi-
cation of zeaxanthin stereoisomers, a chiral HPLC
column was used, and zeaxanthin enantiomers were
confirmed employing chiral liquid chromatography
(LC)–atmospheric pressure chemical ionisation (APcI)-
MS. This allowed us to study whether or not meso-
zeaxanthin appears in the bloodstream immediately after
the ingestion of diets high in non-esterified or esterified
3R,30R-zeaxanthin. To the best of our knowledge, this is
the first report on chiral LC–APcI-MS of pooled human
plasma samples.
Experimental design
Materials
Zeaxanthin stereoisomers (3R,30R, 3R,30S, 3S,30S),
3R,30R,60R-lutein and g-carotene were purchased from
CaroteNature (Lupsingen, Switzerland). Acetone, 2,6-di-
tert-butyl-4-methylphenol, diethyl ether, ethyl acetate,
n-hexane, light petroleum (40–608C), ethanol, and metha-
nol were purchased from Merck (Darmstadt, Germany).
Methyl tert-butyl ether and b-carotene were obtained
from Fluka (Neu-Ulm, Germany). Test kits for the in
vitro determination of plasma triacylglycerol (method TR
210) were purchased from Randox Laboratories GmbH
(Krefeld, Germany); the kits for total cholesterol (method
401) were obtained from Sigma (Taufkirchen, Germany).
All solvents were of analytical grade and were distilled
before use. For HPLC, ultra-pure water obtained from a
Milli-Q 185 apparatus (Millipore, Eschborn, Germany)
was employed. Heat-dried wolfberries were kindly pro-
vided by RichNature Labs Inc. (19011 36th Avenue
West, Suite G, Lynnwood, WA 98036, USA).
Subjects
Twelve human subjects were recruited from the staff and
students of the Institute of Food Science (Hannover). The
six females and six males were divided at random into
two groups of six each. Three of the females used con-
traceptives. None of the individuals suffered from gastro-
intestinal diseases, or took laxatives or drugs lowering
plasma triacylglycerol or cholesterol concentrations. Sup-
plements containing carotenoids or vitamins were not
consumed in the 2 weeks before the first blood sampling
and during the study. The volunteers were requested to
keep to a normal diet but to avoid zeaxanthin-rich food
(for example, red and orange peppers, sea buckthorn,
vitamin-fortified mixed fruit beverages) for the 2 weeks
before and the 3 weeks during the intervention period.
The study protocol was approved by the medical ethics
committee of the Medizinische Hochschule, Hannover,
and the participants provided written informed consent.
Study design
The study was designed as a single-blind cross-over study
over a period of 23 d and consisted of two experimental
days, separated by a 3-week depletion period during
which no supplementation was carried out. At each of
the intervention days, the subjects received a balanced
breakfast with the respective supplementation outlined in
Table 1. Carotenoid administration was performed by
mixing a serving of 150 g commercial whole-milk yoghurt
(3·5 % fat) with 10 g spiked sunflowerseed oil (see later;
p. 709), respectively, resulting in a total amount of 5 mg
3R,30R-zeaxanthin, independent of the non-esterified or
esterified form. The yoghurt was consumed together with
a standardised breakfast, described in an earlier study
(Breithaupt et al. 2003). Due to the amount of oil suspen-
sion (10 g), the total fat content amounted to 29·9 g, the
total energy to 2318 kJ. Blood samples were collected
before (0 h) and after administration (3, 6, 9, 12, and
24 h). After 3 weeks, the cross over was performed (day 2).
Preparation of supplements
Extraction of carotenoids. Carotenoids were extracted
from dried wolfberries using a ternary solvent mixture of
Table 1. Design of the single-blind cross-over study in which
volunteers were divided at random into two groups and the two
intervention days were separated by 3 weeks
Group Day 1 Day 2
Group I (n 6) 3R,30R-zeaxanthin
dipalmitate
Non-esterified
3R,30R-zeaxanthin
Group II (n 6) Non-esterified
3R,30R-zeaxanthin
3R,30R-zeaxanthin
dipalmitate
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light petroleum–ethyl acetate–methanol (1:1:1, by vol.).
Berries (500 g) were ground to a powder which was trans-
ferred into a flask and extracted (1 litre) by mixing
thoroughly. The extract was separated from the plant
tissue employing a Bu¨chner funnel (VWR International
Gmbh, Bruchsal, Germany). To allow for complete extrac-
tion, portions of solvent (200 ml each) were poured onto the
filter cake and sucked off. This step was repeated until the
filter cake was nearly colourless. The resulting extract was
transferred into a separating funnel, washed with water con-
taining a saturated solution of sodium chloride to allow for
good phase separation. The water layer was discarded while
the organic layer was transferred into an Erlenmeyer flask
(VWR International Gmbh), dried with anhydrous sodium
sulfate, filtered, and evaporated to dryness. The resulting
residue was re-dissolved in light petroleum (400 ml) and
stored at 2208C. For LC–APcI-MS analyses of native
zeaxanthin esters, the residue of one additional preparation
(20 g berries) was finally dissolved in n-hexane–iso-
propanol (94·5:5·5 (v/v); 25 ml).
Saponification. A sample (200 ml) of the light pet-
roleum solution (see above) was evaporated to dryness.
The residual oil was dissolved in 500 ml diethyl ether
and divided into five samples for simplified handling.
For saponification, 5 ml methanolic KOH (30 %; w/v)
was added to each portion and the mixture kept at
room temperature for 12 h, protected from light. The
ether phases were washed twice with water (100 ml
each), dried with sodium sulfate, and filtered. The result-
ing residues were dissolved in light petroleum and com-
bined (200 ml) and stored at 2208C. Since the extract
contained predominantly 3R,30R-zeaxanthin (.94
area %; see Fig. 1, chromatogram B, peak 3), it was
not necessary to apply further clean-up steps.
Preparation of diets. For administration in the diet,
the light petroleum was totally removed and the residues
were dissolved in commercial sunflowerseed oil. The
concentration of non-esterified 3R,30R-zeaxanthin was
adjusted to 0·512 (SD 9)mg/g (n 3), and the 3R,30R-zeax-
anthin dipalmitate concentration was set to 504
(SD 5)mg/g (n 3; measured as 3R,30R-zeaxanthin after
saponification) by dilution with oil. Using 10 g oil per
diet, this resulted in an intake of 5 mg 3R,30R-zeaxanthin
in non-esterified or esterified form. Due to the low solu-
bility of non-esterified 3R,30R-zeaxanthin in oil, a stable
emulsion was prepared whereas 3R,30R-zeaxanthin dipal-
mitate formed a clear solution. Since both supplements
were mixed with an excess of yoghurt (150 g), it was
anticipated that there would be no effect on the resorp-
tion behaviour.
Verification of stability. The stability of 3R,30R-zea-
xanthin and 3R,30R-zeaxanthin dipalmitate in sunflower-
seed oil and in yoghurt was tested at the end of the
study. After 3 weeks storing at 2208C, both spiked
oils showed neither degradation nor isomerisation; like-
wise, carotenoid esters were stable in the yoghurt.
Plasma sample preparation
At any blood withdrawal, 5 ml were sampled from each
participant. Immediately after collection, the plasma was
separated from the erythrocytes by centrifugation
(5000 rpm, 10 min) and stored at 2208C in plastic caps.
The extraction of carotenoids from plasma was based on
a method described by Khachik et al. (1997) and was
described by Breithaupt et al. (2003). Extracts obtained
were finally dissolved in 1 ml n-hexane–iso-propanol
(94·5:5·5; v/v), passed through a 0·45mm membrane filter
and subjected to HPLC analysis. To determine possible
losses during preparation, the HPLC peak areas of an
internal standard (1 ml g-carotene solution; 1 mg/l, dis-
solved in n-hexane) were monitored. The recovery from
extractions of various samples was over 95 %. Plasma tria-
cylglycerol and total cholesterol were measured by using
commercial in vitro enzymic test kits.
Analysis and chromatography
Carotenoids were quantified by HPLC on a Hewlett Packard
(Waldbronn, Germany) HPLC Model 1100, using a diode
array detector (450 nm) and a solvent gradient consisting
of n-hexane (A) and iso-propanol (B) (Khachik et al.
2002). The column used was a ChiralPak AD (Chiral Tech-
nologies Europe, Bd. Gonthier d’Andernach, 67404 Illkirch,
France), packed with silica gel (10mm), coated with amy-
lose tris-(3,5-dimethylphenylcarbamate) as selector. The
following gradient (flow rate 0·7 ml/min) was used (min/%
A): 0/94·5; 40/94·5; 50/85; 55/50; 90/50; 91/94·5; 120/
94·5. LC–APcI-MS was run on a Micromass (Manchester,
UK) VG platform II quadrupole mass spectrometer
equipped with an APcI interface, operating in the positive
mode (Breithaupt & Schwack, 2000). For confirmation of
zeaxanthin enantiomers in human plasma, six plasma
samples (group I, day 1) were pooled, evaporated to dryness,
re-dissolved in 200ml n-hexane–iso-propanol (94·5:5·5; v/
v), and analysed with LC–APcI-MS.
Statistics
Results are expressed as mean values and standard
deviations. Plasma concentrations were corrected by the
Fig. 1. HPLC chromatograms (extended sections; diode array
detector, 450 nm) of diluted oil supplements containing native
3R,30R-zeaxanthin dipalmitate (peak 1) from wolfberry (Lycium bar-
barum; chromatogram A) or non-esterified 3R,30R-zeaxanthin (peak
3) obtained after chemical hydrolysis (chromatogram B). (2), Peak
corresponding to b-cryptoxanthin. Peak assignment was carried out
using liquid chromatography–atmospheric pressure chemical ionis-
ation-MS analysis.
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individual fasting 3R,30R-zeaxanthin concentrations. Areas
under the curve (AUC; 0–24 h) were determined automati-
cally by the trapezoidal rule after the subtraction of fasting
plasma 3R,30R-zeaxanthin concentrations. For comparison
of the plasma concentrations and the AUC of the two
groups and days, two-sided F and t tests were employed.
P values ,0·05 were considered statistically significant.
All statistics were performed with Microsoft Excel 2000.
Results
Determination of carotenoids was carried out using an
HPLC system equipped with a chiral phase (Khachik
et al. 2002). Thus, the separation of 3R,30R,60R-lutein
and zeaxanthin stereoisomers was achieved without further
derivatisation. Other plasma carotenoids (for example, b-
carotene, lycopene) were separated as well but were not
studied in detail. The comparatively long running time
(125 min) was necessary to obtain a good separation of
the zeaxanthin stereoisomers and to allow for complete
cleaning of the column. Fig. 1 depicts two chromatograms
illustrating the constitution of both oil supplements: chro-
matogram A corresponds to the native xanthophyll pattern
of wolfberries. Besides the main component, 3R,30R-zea-
xanthin dipalmitate (peak 1), only small amounts of other
xanthophylls were present. Chromatogram B corresponds
to a saponified sample. As anticipated, 3R,30R-zeaxanthin
(peak 3) formed the main component (.94 area %),
accompanied by low amounts of non-esterified b-crypto-
xanthin (peak 2). The enlargement of the peak width of
3R,30R-zeaxanthin (peak 3) in trace B is due to the iso-
cratic method used for chromatographic separation. How-
ever, equal peak areas proved that the concentrations
were identical. As the concentrations of carotenoids other
than 3R,30R-zeaxanthin dipalmitate are very low, they
probably will not affect the absorption behaviour of
3R,30R-zeaxanthin dipalmitate and 3R,30R-zeaxanthin.
Co-chromatography with authentic 3R,30R-zeaxanthin
reference material proved zeaxanthin to be present only
in the 3R,30R-form. Since saponification with methanolic
KOH does not influence stereochemistry, it was concluded
that native 3R,30R-zeaxanthin dipalmitate (peak 1) of wolf-
berries had the same enantiomeric profile. This observation
is in accordance with the results of Maoka et al. (1986)
who found that zeaxanthin in higher plants predominantly
possesses the 3R,3R0 configuration (.99 %). Conse-
quently, the diets administered to the volunteers contained
3R,3R0-zeaxanthin or 3R,3R0-zeaxanthin palmitate,
respectively.
All participants were instructed to consume a low-caro-
tenoid diet 2 weeks before and during the study in order to
minimise the plasma zeaxanthin level. Fasting baseline
concentrations of 3R,30R-zeaxanthin averaged therefore
only 0·095 (SD 0·009, range 0·08–0·12) mmol/l (n 12).
Further characteristics of the participants (fasting plasma
concentrations of cholesterol and triacylglycerol) on both
intervention days are given in Table 2.
Confirmation of carotenoids in human plasma by
LC–APcI-MS has been described earlier by Khachik
et al. (1992) who used a nitrile-bonded column for separ-
ation. To the best of our knowledge, chiral LC–APcI-MS
has not been used to confirm zeaxanthin stereoisomers in
human plasma. Peak assignment was carried out in the
positive ionisation mode using a chiral phase with amylose
tris-(3,5-dimethylphenylcarbamate) as selector (Khachik
et al. 2002). For unequivocal identification, characteristic
ions (zeaxanthin m/z 569 [M þ H]þ; lutein m/z 551
[M þ H-H2O]þ) and UV/Vis spectra (zeaxanthin 422/448/
472 nm; lutein 418/442/470 nm) were used. Fig. 2 shows
the chromatographic separation (extended section) of a
standard mixture (line A) containing zeaxanthin enantio-
mers (3R,30R (peak 3); 3R,30S (meso) (peak 4); 3S,30S
(peak 5)) and lutein (peak 6) by LC–APcI-MS and the
respective mass traces used for identification (line B,
lutein m/z 551 [M þ H-H2O]þ; line C, zeaxanthin enantio-
mers m/z 569 [M þ H]þ). Since lutein possesses one a-
ionone end ring, water is easily lost from the quasimolecu-
lar ion, resulting in the formation of a predominant frag-
ment ion at m/z 551. The zeaxanthin stereoisomers (line
C) showed the anticipated quasimolecular ions (m/z 569).
Lines D, E, and F correspond to the separation of a
pooled plasma sample, obtained 24 h after the ingestion
of 3R,30R-zeaxanthin dipalmitate from wolfberries. The
absence of mass signals at the typical retention times of
meso- (peak 4) and 3S,30S-zeaxanthin (peak 5) unambigu-
ously proved the absence of both enantiomers in the
plasma (lines E and F). Thus, besides other carotenoids
as 3R,30R,60R-lutein (peak 6) and lycopene (peak 7), only
the 3R,30R isomer of zeaxanthin (peak 3) was detected.
The same results were found in pooled samples of other
Table 2. Characteristics of the participants
(Mean values and standard deviations)
Day 1 Day 2
Mean SD Mean SD Mean SD
Age (years)* 26·8 5·4
BMI (kg/m2)* 23·1 2·9
Fasting plasma concentrations†
Total cholesterol (mmol/l) 4·17 0·55 4·13 0·74
Triacylglycerol (mmol/l) 1·25 0·61 1·13 0·45
3R,30R-zeaxanthin (mmol/l) 0·09 0·01 0·10 0·01
* n 12 (six males and six females).
† n 12 (days 1 and 2 separate).
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groups. Fig. 2 demonstrates that UV/Vis detection at
450 nm using a diode array detector even provides enough
sensitivity for the analysis of pooled plasma samples. As
potential cis isomers of lutein and zeaxanthin elute con-
siderably after their corresponding all-trans forms (Kha-
chik et al. 2002), co-elutions can be excluded. Additional
LC–APcI-MS analyses gave no evidence for the presence
of zeaxanthin esters. This is in accordance with the results
of previous studies conducted with esterified lutein or b-
cryptoxanthin as dietary supplements (Bowen et al. 2002;
Breithaupt et al. 2003).
To determine the course of 3R,30R-zeaxanthin increase,
the average concentrations of plasma 3R,30R-zeaxanthin
of all the subjects were plotted v. the sampling time
(Fig. 3). No matter whether the diets were supplemented
with non-esterified or esterified 3R,30R-zeaxanthin, the
plasma concentration increased significantly (P,0·05),
showing a maximum between 9 and 24 h in each case.
The maximal plasma concentrations reached after supple-
menting non-esterified 3R,30R-zeaxanthin were lower
with smaller standard deviations (day 1, 0·044 (SD
0·008–0·013) mmol/l), compared with the supplementation
with 3R,30R-zeaxanthin palmitate, where higher concen-
trations and higher standard deviations were observed
(day 1, 0·105 (SD 0·006–0·028) mmol/l). On the second
intervention day the same situation appeared. Due to the
high standard deviations observed after the ingestion of
3R,30R-zeaxanthin dipalmitate, the concentration curves
were statistically not distinguishable according to two-
sided F and t tests (P.0·05). In order to account for poten-
tial variations in the total triacylglycerol (and cholesterol)
concentrations, the individual values were corrected for
both triacylglycerol and cholesterol. Each individual
3R,30R-zeaxanthin concentration was divided by the
Fig. 2. Liquid chromatography (LC)–atmospheric pressure chemical ionisation (APcI)-MS analysis (extended sections) of a standard mixture
(trace A) of zeaxanthin stereoisomers (3R,30R (peak 3), 3R,30S (peak 4) and 3S,30S (peak 5)) and 3R,30R,60R-lutein (peak 6), and mass traces
for lutein (m/z 551) (trace B) and zeaxanthin (m/z 569) (trace C). Trace D corresponds to the LC–APcI-MS chromatogram (diode array detec-
tor, 450 nm) of a pooled plasma sample after ingestion of 3R,30R-zeaxanthin palmitate (3R,30R-zeaxanthin (peak 3), 3R,30R,60R-lutein (peak 6),
and lycopene (peak 7) and the corresponding mass traces for lutein (m/z 551) (trace E) and zeaxanthin (m/z 569) (trace F).
Fig. 3. Plasma 3R,30R-zeaxanthin concentrations on day 1 (A) and day 2 (B) dependent on sampling time after ingestion of a single dose of
non-esterified or esterified 3R,30R-zeaxanthin (5 mg). Values are means, with standard deviations represented by vertical bars. (A), Non-esteri-
fied 3R,30R-zeaxanthin; (W), 3R,30R-zeaxanthin palmitate.
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respective volunteer’s mean triacylglycerol (or cholesterol)
concentration and multiplied by the mean triacylglycerol
(or cholesterol) concentration of all participants as a refer-
ence point. 3R,30R-zeaxanthin plasma responses adjusted
for triacylglycerol are shown in Fig. 4. Standardisation
for total cholesterol revealed the same results (data not
shown), proving that the results were not influenced by
the individual serum lipid profiles of the human subjects.
To characterise the absorption behaviour of non-esteri-
fied and esterified 3R,30R-zeaxanthin, a summary value
implicating all sampled points, not only the maxima, is
required. As suggested by Yao et al. (2000), the AUC
was generated from the respective diagrams. This allows
for an estimation of how effectively either of the two
forms is resorbed. A two-sided F test (P,0·05) revealed
that the AUC for supplementing non-esterified 3R,30R-
zeaxanthin on days 1 and 2 had unequal variances; hence
the corresponding t test (P,0·05) had to be employed.
Consequently, volunteers receiving the same diets on
different intervention days were not pooled. The mean
AUC (mmol/l £ h) calculated that way for each day and
group were as follows: non-esterified zeaxanthin (day 1),
0·492 (SD 0·18); zeaxanthin palmitate (day 1), 1·080 (SD
0·25); non-esterified zeaxanthin (day 2), 0·506 (SD 0·003);
zeaxanthin palmitate (day 2), 1·178 (SD 0·18). Supplemen-
tation with 3R,30R-zeaxanthin palmitate resulted in signifi-
cantly higher AUC on both intervention days (P,0·05);
thus, AUC were distinguishable. Standardisation of the
AUC to total triacylglycerol or cholesterol did not
change the results. Therefore, serum triacylglycerol (or
cholesterol) concentrations of the subjects had no influence
on the results.
Discussion
Fasting baseline concentrations of zeaxanthin given in the
literature range between 35 and 260 nmol/l (35 nmol/l
(Khachik et al. 1992); 66 nmol/l (Grobusch-Klipstein
et al. 2000); 260 nmol/l (Bo¨hm & Bitsch, 1999)). The fast-
ing baseline 3R,30R-zeaxanthin concentrations determined
were well within this range (81–116 nmol/l). Both total
triacylglycerol and cholesterol concentrations were within
the normal range for all the subjects (desirable concen-
trations of triacylglycerol and cholesterol are ,1·25 and
,5·18 mmol/l respectively; Jordan et al. 1995). After
consumption of the 3R,30R-zeaxanthin-fortified diets, the
concentration maxima in the plasma were reached between
9 and 24 h after administration, whereas the highest con-
centration was 122 nmol/l (69mg/l). Based on the assump-
tion that 4 % of the body weight is plasma (2·4 litres
plasma/60 kg body weight; Barua, 1999), this corresponds
to an absolute amount of 166mg 3R,30R-zeaxanthin,
which in turn corresponds to a percentage of 3·3 % of the
administered dose. This is in accordance with data given
in the literature, stating a low efficiency of carotenoid
absorption, reported to range from 5 to 50 % (Olson,
1994). Interestingly, the amount absorbed corresponded
to that found in an earlier study with b-cryptoxanthin
esters (Breithaupt et al. 2003), although the carotenoid
concentration administered in the present study was
nearly four times higher. This underlines the tendency in
man to absorb xanthophylls relatively poorly. The majority
might have been metabolised to apocarotenals, which were
not studied, or excreted through the gastrointestinal tract.
The only stereoisomer found in the plasma after the inges-
tion of 3R,30R-zeaxanthin palmitate was 3R,30R-zeax-
anthin. Thus, metabolism to the 3S,30S enantiomer or the
meso form is to be excluded in the plasma, in particular
during the time period studied (24 h).
On comparison of the mean plasma concentrations after
supplementing with non-esterified and esterified 3R,30R-
zeaxanthin, a higher standard deviation in the case of the
esterified diet was observed. This made the absorption
curves not distinguishable on both intervention days. How-
ever, the tendency agrees with earlier results using non-
esterified and esterified b-cryptoxanthin (Breithaupt et al.
2003), where the ingestion of xanthophyll esters resulted
in higher standard deviations, too. A reason for this beha-
viour is as yet unknown, though a possible explanation
could be different lipase activity of individual human
subjects.
AUC, which are directly proportional to the bioavailabil-
ity (Yao et al. 2000), were calculated for each day and
group. As the variances of the volunteers receiving non-
esterified 3R,30R-zeaxanthin were unequal when compar-
ing both intervention days, the respective groups could
not be pooled, resulting in four mean AUC, two for each
day. The AUC resulting after the ingestion of 3R,30R-zea-
xanthin palmitate exceeded those obtained after the con-
sumption of non-esterified 3R,30R-zeaxanthin roughly by
Fig. 4. Plasma 3R,30R-zeaxanthin concentrations standardised to triacylglycerol plasma concentrations on day 1 (A) and day 2 (B). Values are
means, with standard deviations represented by vertical bars. (A), Non-esterified 3R,30R-zeaxanthin; (W), 3R,30R-zeaxanthin palmitate.
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a factor of two on both intervention days. The comparison
of the AUC reveals that the low 3R,30R-zeaxanthin concen-
tration in plasma is not a result of low enzymic hydrolysa-
tion rates. If that were the case, it is anticipated that the
AUC would be not distinguishable. The relatively low
plasma 3R,30R-zeaxanthin concentration is due, rather, to
the low absorption tendency of the non-esterified form,
no matter whether the xanthophyll is administered in its
non-esterified or esterified form. In contrast to earlier
studies (Bowen et al. 2002; Breithaupt et al. 2003), the
plasma response after supplying esterified 3R,30R-zea-
xanthin was significantly higher than the response after
the administration of the non-esterified form. The reason
for an enhanced bioavailability of esterified 3R,30R-zea-
xanthin is not yet known. A possible explanation could
be the apolar nature of 3R,30R-zeaxanthin dipalmitate in
comparison with the more polar non-esterified form,
which allows for the effective formation of micelles,
needed before lipase activity. A satisfactory explanation
still requires further investigation.
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